Cardinal Health will pay $13M to settle kickback allegations

Pharmaceutical distributor Cardinal Health has agreed to pay more than $13 million to settle allegations it gave doctors kickbacks to purchase medicines paid for by federal health programs.

The Department of Justice said Monday that the Ohio-based drug distributor violated the Anti-Kickback Statute by offering to pay physician practices upfront discounts to buy certain pharmaceuticals paid for by Medicare.

Under the rule, distributors are permitted to offer commercially available discounts to customers who meet certain conditions, but Cardinal Health failed to meet those requirements.

“Cardinal Health thought it hit upon a surefire moneymaker by paying kickbacks to doctors, which cost health benefit programs millions of dollars in potentially fraudulent claims,” Joseph R. Bonavolonta, special agent in charge of the Federal Bureau of Investigation, Boston Division, said in a statement. “Anyone involved in, or entertaining, similar activity should know that healthcare fraud is a priority for the FBI, and we will pursue anyone trying to profit from this country’s vital healthcare system.”

Cardinal Health did own up to certain facts as part of the $13.13 million settlement but did not admit to any liability, according to Reuters.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.